Table 2 Baseline characteristics of all ICC patients

Age, year

1.112

0.292

 < 60

124 (54.6)

97 (49.5)

 ≥ 60

103 (45.4)

99 (50.5)

Gender

0.255

0.614

 Female

104 (45.8)

85 (43.4)

 Male

123 (54.2)

111 (56.6)

History of hepatitis B infection

 < 0.001

0.983

 Negative

145 (63.9)

125 (63.8)

 Positive

82 (36.1)

71 (36.2)

Hepatolithiasis

11.634

0.001

 Negative

194 (85.5)

187 (95.4)

 Positive

33 (14.5)

9 (4.6)

ALT (U/L)

4.755

0.029

 < 50

173 (76.2)

166 (84.7)

 ≥ 50

54 (23.8)

30 (15.3)

AST (U/L)

2.104

0.147

 < 40

162 (71.4)

152 (77.6)

 ≥ 40

65 (28.6)

44 (22.4)

Bilirubin (umol/L)

0.298

0.585

 < 21

189 (83.8)

167 (85.2)

 ≥ 21

38 (16.7)

29 (14.)

AFP (ng/mL)

5.890

0.015

 < 7

148 (65.2)

149 (76.0)

 ≥ 7

79 (34.8)

47 (24.0)

CEA (ng/mL)

2.303

0.129

 < 5

155 (68.3)

120 (61.2)

 ≥ 5

72 (31.7)

76 (38.8)

CA19-9 (U/mL)

0.008

0.930

 < 37

82 (36.1)

70 (35.7)

 ≥ 37

145 (63.9)

126 (64.3)

Tumor differentiation

0.607

0.436

 Well-moderate

172 (75.8)

142 (72.4)

 Poor

55 (24.2)

54 (27.6)

Tumor number

0.090

0.765

 1

165 (72.7)

145 (74.0)

 ≥ 2

62 (27.3)

51 (26.0)

Tumor size (cm)

0.019

0.890

 < 5

75 (33.0)

66 (33.7)

 ≥ 5

152 (67.0)

130 (66.3)

HTS grade

3.257

0.196

 1

86 (37.9)

61 (31.1)

 2

81 (35.7)

86 (43.9)

 3

60 (26.4)

49 (25.0)

PT (s)

12.30(11.50–13.10)

11.90(11.30–12.78)

1.569

0.117

INR

0.97(0.88–1.07)

1.00(0.93–1.06)

0.431

0.667

APTT (s)

33.00(28.90–37.70)

31.30(27.50–35.73)

1.281

0.201

White blood cell count (10^9/L)

6.34(5.01–8.27)

6.29(5.03–7.74)

1.080

0.281

Neutrophil count (10^9/L)

4.29(3.25–5.70)

4.40 (3.28–5.39)

0.829

0.408

Lymphocyte count (10^9/L)

1.52(1.10–1.88)

1.59(1.21–1.87)

-0.525

0.600

Platelet count (10^9/L)

199.00(161.00–259.00)

205.00(162.50–259.00)

-0.341

0.733

Hemoglobin count (g/L)

133.00(118.00–143.00)

132.20(121.00–144.00)

-1.379

0.169

Albumin (g/L)

4.509

0.034

 ≤ 30

211 (93.0)

191 (97.4)

 > 30

16 (7.0)

5 (2.6)